A head-to-head ADHD study found comparable driving-simulator performance with lisdexamfetamine and extended-release methylphenidate. Because the trial lacked placebo, it could not quantify how much either improved performance over no active treatment.
Madaan and colleagues used a randomized double-blind crossover design in young adults with ADHD. Doses of each medication were optimized before a laboratory simulator assessment extending across 15 hours. Forty-four participants completed the study. The principal outcome was a composite Tactical Driving Quotient, with clinical improvement ratings as a secondary measure.
The estimated treatment difference in the principal driving score was small, with a confidence interval spanning zero. The authors reported comparable effects across the tested period. This comparison concerns two active treatment regimens in a selected clinical population. It does not establish that either medicine produces the same response in every participant or that no meaningful individual preferences or adverse effects exist.
The authors explicitly identified the absence of placebo as a limitation for estimating absolute simulator improvement. Practice, optimized dosing and the controlled testing environment also distinguish the study from ordinary traffic. Fifteen hours was the final assessment period, not proof that an effect abruptly ended afterward. Methylphenidate and lisdexamfetamine are pharmacologically distinct and should not both be called amphetamine. Neither the active-comparator result nor the clinical rating supplies a drug-level impairment threshold. The useful conclusion is comparative performance under the tested protocols, while real-world crash reduction and the magnitude of benefit over untreated ADHD remain separate questions.
See why comparative trial claims depend on design and statistical testing.